. Author manuscript; available in PMC: 2019 Mar 19.

Published in final edited form as: Cell Rep. 2019 Feb 5;26(6):1544–1556.e8. doi: 10.1016/j.celrep.2019.01.043

Table 1.

Lethal Compound Potency in Control and MRP1-Overexpressing Cells

Compound	H1299^Control	H1299^MRP1	U-2 OS^Control	U-2 OS^MRP1
Vincristine	2.8 (1.9–4.2) nM	32 (19–54) nM	3.3 (1.4–8.2) nM	53 (18–65) nM
Doxorubicin	0.2 (0.1–0.3) μM	1.0 (0.8–1.4) μM	0.2 (0.1–0.3) μM	3.7 (1.9–13) μM
Erastin2	80 (65–105) nM	1.1 (0.1–12) nM	130 (100–170) nM	47 (20–77) nM
RSL3	140 (54–530) nM	0.055 (0.015–0.19) nM	5.9 (4.8–7.2) μM	1.8 (0.8–42) μM
ML162	140 (46–870) nM	0.3 (0.1–0.6) nM	4.9 (4.4–5.5) μM	3.4 (2.6–4.6) μM
BSO	>20 mM	83 (67–100) nM	N.D.	N.D.
Thapsigargin	3.7 (3.4–4.1) nM	5.4 (2.4–11) nM	1.4 (0.9–2.0) nM	2.3 (0.4–4.1) nM
Bortezomib	21 (12–47) nM	25 (16–43) nM	12 (6.9–27) nM	7.4 (4.6–14) nM

For vincristine, doxorubicin, erastin2, RSL3, ML162, BSO, and thapsigargin treatments, cell viability was assayed using PrestoBlue. For bortezomib treatment, cell viability was assayed by counting of SYTOX Green⁺ dead cells. Erastin2, RSL3, ML162, and BSO effects were assayed after 48 h of treatment; doxorubicin and thapsigargin were assayed after 72 h of treatment. Vincristine was assayed after 48 or 72 h of treatment in H1299 and U-2 OS cells, respectively. Data represent means and 95% confidence intervals (in brackets). N.D., not determined.